AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer Published: May 7, 2021 | Tags: AstraZeneca, Imfinzi, durvalumab, Tremelimumab, P-III, POSEIDON Study, Stage IV Non-Small Cell Lung Cancer Merck and… Read More »PharmaShots Weekly Snapshots (May 03 – 07, 2021)
ProQR Therapeutics Signs an Exclusive Worldwide License Agreement with Yarrow to Develop Therapies for Non-Ophthalmic Target
Shots: ProQR is eligible to receive ~$115M up front and milestone along with royalties on the sales of any resulting products during the royalty term and gets the right to receive a percentage of equity in the form of Yarrow shares Yarrow has in-licensed exclusive… Read More »ProQR Therapeutics Signs an Exclusive Worldwide License Agreement with Yarrow to Develop Therapies for Non-Ophthalmic Target
ProQR Therapeutics has encouraging data from an early-stage study evaluating its treatment for vision loss in the rare, inherited disorder Usher syndrome. The biotech now plans to advance its RNA therapy to two pivotal studies later this year.